A CD47/SIRPα blockade provokes antitumor activity by inducing tumor cell phagocytosis by macrophages and activating the cross-presentation of tumor antigens to CD8+ T cells by DCs (Figure 2). The gene discussed is CD8A; the disease is neoplasm.